Skip to main content
. Author manuscript; available in PMC: 2017 Mar 1.
Published in final edited form as: Mol Cancer Res. 2015 Dec 11;14(3):296–301. doi: 10.1158/1541-7786.MCR-15-0392-T

Table 2.

Response to biomarker-targeted therapy in patients with metastatic KRAS/BRAF wild-type, RTK/MAP2K1–altered colorectal carcinomas

RTK/MAP2K1 Alteration Targeted therapy Duration of
therapy		 Outcome Notes
ERBB2 amplification (FC = +38.9) Cetuximab + irinotecan 5 Stable disease for 5 months Previously treated with
    FOLFIRI without progression
ERBB2 amplification
    (FC = +8.5), ERBB2 p. V842I		 Irreversible inhibitor of
    EGFR/ ERBB2		 2 RECIST stable disease and
    mixed response
Panitumumab + irinotecan 2 Progression of disease Irinotecan naïve
ERBB2 amplification,
    ERBB2 p. S310F		 Dual ERBB2/ EGFR inhibitor 2 Progression of disease
ERBB2-GRB7 fusion, amplified Cetuximab + irinotecan 2 Progression of disease
Monoclonal anti-ERBB2
    + capecitabine		 2 Progression of disease
Irreversible inhibitor of
    EGFR/HER2		 1.5 Progression of disease
MAP2K1 p. K57E Cetuximab + capecitabine
    + Avastin		 5 Progression of disease
Cetuximab + irinotecan 2 Progression of disease Irinotecan naïve
MAP2K1 p. K57N Panitumumab + irinotecan 2 Progression of disease Previously treated
    with irinotecan